Evi

Urinalysis Analyzers: Large Capabilities in Every Size Device

Urine chemistry analysis, often conducted in a physicians office practice, can be instrumental in the detection of a wide array of ailments; UTIs, diabetes, several cancers, metabolic disorders, cardiovascular and kidney diseases. The estimated global market for urinalysis tests is well in excess of $600 million per year and is growing strongly. For such a fundamental, extensive and economic...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using Proellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...

Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme

CAMBRIDGE, U.K. 2nd July 2007 - CeNeS Pharmaceuticals (AIM:CEN)("CeNeS" or "the Company") the Cambridge-based biopharmaceuticalcompany today announced that a paper published this week in CNSDrugs(1) further supports the hypothesis that acatechol-O-methyltransferase (COMT) inhibitor that acts in thebrain would be a useful agent to address profound cognitivedeficits in schizophrenia and bi...

Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma

- 100 percent of patients treated with VELCADE, cyclophosphamide,and prednisone alive at one year - KOS, Greece, June 28, 2007 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. today reported on the presentation of resultsfrom clinical trials of VELCADE based therapies that showed highcomplete remission / complete response(1) (CR) rates in previouslytreated multiple myeloma (MM) p...

Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates

'Superbug' Prevalence Data from 1,237 Facilities DemonstratesPublic Health Threat; Colonization and Infections Span All States,Across Healthcare Facility Units SAN JOSE, Calif., June 25, 2007 /PRNewswire-USNewswire/ -- TheAssociation for Professionals in Infection Control and Epidemiology(APIC) today released initial results from a nationwide study of1,237 U.S. healthcare facilities, exam...

Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer

PHILADELPHIA, June 25, 2007 /PRNewswire-USNewswire/ -- Childhoodcancers are fortunately rare, but among them, neuroblastoma is aspecial case, accounting for 7 percent of all childhood cancers,but 15 percent of childhood cancer deaths. It typically occurs as asolid tumor in the abdomen, but also in the neck, chest, andpelvis, developing in the network of the body's sympathetic nervoussyst...

Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting

SAN DIEGO--(BUSINESS WIRE)--Jun 6, 2007 - Inovio BiomedicalCorporation (AMEX:INO), focused on the development of DNA vaccinesfor cancers and infectious diseases and a novel alternative tosurgery to treat localized cancers, announced today the companydelivered multiple presentations on preclinical study results andnew device innovations relating to its electroporation-mediated DNAdelivery te...

Hemispherx Presents Evidence of Ampligen Synergies with Existing Antivirals at International Avian Influenza Conference

PARIS--(BUSINESS WIRE)--Jun 4, 2007 - Hemispherx Biopharma, Inc.(AMEX: HEB), a biopharmaceutical company engaged in the clinicaldevelopment of new drug entities for the treatment of pandemicdisease threats, announced today a new scientific report on theactivity of its experimental therapeutic Ampligen(R) in combinationwith approved anti-influenza agents against highly pathogenic avianinflue...

Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma

Data Presented at the ASCO Cancer Conference NORTH HOLLYWOOD, Calif., and CHICAGO, June 04, 2007 /PRNewswire/-- The International Myeloma Foundation (IMF)-supporting researchand providing education, advocacy and support for myeloma patients,families, researchers and physicians-today said that data from afollow-up to a Phase 3 multi- national clinical trial shows thecombination of DOXIL(R)...

New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma

- Positive data on subcutaneous administration show potential fornew option to improve convenience for patients - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. today announced the presentation of positivedata for VELCADE, the market-leading therapy for patients withmultiple myeloma (MM) who have received at least one prior therapy.These data include resu...

Medicure's MEND-CABG Trial Results Published in Peer Reviewed Journal

WINNIPEG, Manitoba - (May 31, 2007) Medicure Inc. (TSX:MPH;Amex:MCU), a cardiovascular focused biopharmaceutical company,today announced that the results from its Phase 2 MEND-CABG trialare featured in a peer reviewed article in the June edition of TheJournal of Thoracic and Cardiovascular Surgery, published by theAmerican Association of Thoracic Surgery. The article, titled, "Effects of...

Review of Nexavar Data Presented at ASCO 2007- Investor Conference Call on June 4, 2007

Leverkusen, Germany, May 31, 2007- Results from variousclinical studies including a pivotal Phase III trial in patientswith advanced hepatocellular carcinoma, or primary liver cancerwith Nexavar (sorafenib) tablets will be presented at the AnnualMeeting of the American Society of Clinical Oncology (ASCO) inChicago, USA from June 1 - 5, 2007. On this occasion a conference call for i...

Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD

SEATTLE--(BUSINESS WIRE)--May 29, 2007 - Mitopharm Corporation,Inc. (Pink Sheets:MTPM), releases the results of a research paperwhere Professor Dr. Robert Ko published the beneficial effects ofSchisandrin B, the precursor of (-) Schisandrin B - a noveldiscovery by Dr. Ko - on Ischemic Heart Disease. In a research paper entitled "SCHISANDRIN B PROTECTS AGAINSTMYOCARDIAL ISCHEMIA-REPERFUSIO...

Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos' Bevirimat

WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2007 - PanacosPharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology companydedicated to developing the next generation of antiviraltherapeutic products, today announced the results of a new studyindicating that HIV resistant to Protease Inhibitors (PI) may havereduced potential for the development of resistance to the HIVmaturation inhibitor bevirim...

Salix Pharmaceuticals Previews Digestive Disease Week 2007

RALEIGH, N.C.--(BUSINESS WIRE)--May 17, 2007 - SalixPharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that results of18 investigator-initiated trials related to the Company's productswill be presented at Digestive Disease Week(R) 2007, which will beheld May 19-24, 2007. Digestive Disease Week is considered thelargest and most prestigious meeting in the world for the GIprofessional. Every...

Successful Human Clinical Trial of Chrono Therapeutic's Drug/Device Combination Product - ChronoDose

Trial Convincingly Proves Functionality in Humans of CTI'sProgrammable, Pulsatile, Passive Transdermal Drug Delivery Device -ChronoDose BASEL, Switzerland and TRENTON, N.J., May 03, 2007 /PRNewswire/-- Chrono Therapeutics Inc. (CTI) announced today the successfulcompletion of its first phase human clinical trial of itsprogrammable, pulsatile, passive transdermal drug/devicecombination pr...

Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than Vaccines Used in Previous Years

ROCHESTER, N.Y., May 02, 2007 /PRNewswire/ -- A new Harris Pollsuggests that the flu vaccine used before last winter may have beenless effective than the vaccines used in some previous years. Theadults who had flu shots before last winter were only 24 percentless likely to get the flu than those who were not vaccinated. Thedifferences were larger in two previous Harris Polls on the samet...

Evidence of Nanoparticles Found in Plaque-Filled Arteries

ROCHESTER, Minn., April 30. 2007-- Scientific evidenceincreasingly links arterial calcification to the presence ofnanosized particles -- so small that some scientists questionwhether a nanoparticle can live and, if so, play a viable role incausing disease. A new Mayo Clinic study cites evidence showing the presence ofnanoparticles near plaque-filled arteries in animal models....

Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers

- Journal of Clinical Oncology publishes first clinical study ofHGS-ETR1 - ROCKVILLE, Md., April 27, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today reported that clinical and preclinicalevidence continues to emerge demonstrating that its TRAIL receptorantibodies, HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab), havesignificant potential for use in the treatment of a bro...

Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer

IRVING, Texas--(BUSINESS WIRE)--Apr 25, 2007 - ReataPharmaceuticals, Inc. today announced the publication of a reviewarticle covering the company's Synthetic Triterpenoid programs inthe May 2007 issue of the prestigious journal "Nature ReviewsCancer." The article, "Triterpenoids and rexinoids as multifunctionalagents for the prevention and treatment of cancer," by researchersand Reata sc...

CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal

LOS ANGELES--(BUSINESS WIRE)--Apr 23, 2007 - CytRx Corporation(NASDAQ:CYTR) today announced that the RNA interference (RNAi)delivery technology exclusively licensed to its majority-ownedsubsidiary, RXi Pharmaceuticals Corporation (RXi), has beenpublished in the April 2007 issue of peer-reviewed scientificjournal ACS Chemical Biology. The technology was developed by RXiCo-founder, Scientific...

Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, global biopharmaceuticalcompany, discussed results from two pre-clinical studies thatprovide evidence for chemotherapy induced angiogenesis andrationale for combining nab-paclitaxel (ABRAXANE(R) for InjectableSuspension (paclitaxel protein-bound particles for injectablesuspension) (albumin-bou...

Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C

BARCELONA, Spain--(BUSINESS WIRE)--Apr 14, 2007 - In a late-breakerpresentation at the 42nd Annual Meeting of the European Associationfor the Study of the Liver (EASL), researchers today presented datafrom a planned interim analysis of the PROVE 1 clinical trial,which is the first trial to evaluate short-duration therapy withthe investigational hepatitis C protease inhibitor telaprevir (TVR,...

Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL)

BARCELONA, Spain--(BUSINESS WIRE)--Apr 11, 2007 - New datasupporting the clinical development of telaprevir (VX-950), one ofthe most advanced investigational oral protease inhibitors for thetreatment of hepatitis C virus (HCV) infection, will be presentedat the 42nd Annual Meeting of the European Association for theStudy of the Liver (EASL) in Barcelona this week. In total, nineabstracts re...

Pivotal Phase III Findings With Investigational Drug Cleviprex (Clevidipine) Demonstrate Perioperative Blood Pressure Control In Cardiac Surgery

First Presentation of Comparative Data from ECLIPSE, Largest SafetyProgram of Intravenous Antihypertensive Agents NEW ORLEANS, March 27, 2007 /PRNewswire-FirstCall/ -- Favorablefindings of the investigational drug Cleviprex(TM) (clevidipine)compared to current intravenous antihypertensive agents incontrolling perioperative hypertension -- a potentially harmfulelevation in blood pressure j...

Study Presented at ACC Shows Treatment With ISIS 301012 Added to Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C Levels of Less Than 70 mg/dL

* ISIS 301012 coadministered with statins for only five weeks at400 mg/week lowered LDL-C 47% beyond the levels achieved withstatins alone, with similarly favorable effects on otheratherogenic lipids NEW ORLEANS and CARLSBAD, Calif., March 26, 2007/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced newresults from its Phase 2 clinical trial of ISIS 301012coadministered with st...

Isotechnika's independent data monitoring committee conducts review of phase 2b kidney transplant trial

- Company Set to Host Evening Symposium at ATC - EDMONTON, March 27 /CNW/ - Isotechnika Inc. announced today thatan independent data monitoring committee (DMC) has met and reviewedthe interim data from the Phase 2b kidney transplant (PROMISE)trial. The review included 3 month data from approximately 1/3 ofthe anticipated 332 patients to be enrolled. The DMC hasrecommended that...

Inflazyme Announces Outcome of Review of Phase 2b Asthma Study: Potential Mitigating Factors Identified which Prevent Clear Interpretation of Results

RICHMOND, British Columbia, March 12, 2007--InflazymePharmaceuticals Ltd. (TSX: IZP). As announced on January 29, 2007,the preliminary results of the Phase 2b CAPSICS study withIPL512,602 showed no statistical or clinical difference betweenpatients who received drug or placebo. However, the placeboresponse was surprisingly large and consistent across a number ofthe end-points, which prom...

British Journal of Cancer Reports Preclinical Evidence of Positive Effect of Rice Bran on Intestinal Cancer

Study Shows 51% Reduction in Intestinal Adenomas SuggestingPossible Beneficial Mediation in the Prevention of IntestinalCancer EL DORADO HILLS, Calif., March 07, 2007 /PRNewswire/ -- NutraCeaannounced today the results of a study on the effect of rice branon the number of intestinal adenomas in cancerous mice, publishedin the January 9, 2007 online edition of the prestigious BritishJourn...